Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $1 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 27.3% | -33.1% | -18.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.4% | 73.3% | 73.1% | 74.3% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 24.4% | 76.8% | 41.4% | 59.1% |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -2.4% | 39.7% | -17% | 23.7% |
| EPS Diluted | -0.22 | 2.94 | -1.98 | 3.34 |
| % Growth | -107.5% | 248.5% | -159.3% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | $0 |